HDFC Life Insurance entered Biocon with 1.65 crore shares, representing a 1.01% stake, valued at ₹722.38 crore at ₹437.95 apiece. This appears to be a new position for HDFC Life Insurance in Biocon.
A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.
HDFC Life Insurance Company Limited, institutional investor in Indian equities
